PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle
about
PPARs and the cardiovascular systemInverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasionSirtuin 1 Mediates the Actions of Peroxisome Proliferator-Activated Receptor δ on the Oxidized Low-Density Lipoprotein-Triggered Migration and Proliferation of Vascular Smooth Muscle Cells.Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.Knockdown of PPAR δ gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model.Dihydroaustrasulfone alcohol inhibits PDGF-induced proliferation and migration of human aortic smooth muscle cells through inhibition of the cell cycle.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Vascular PPARδ protects against stroke-induced brain injury.Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor δ (PPARδ) in human cholangiocarcinoma.Vascular effects of prostacyclin: does activation of PPARδ play a role?Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expressionPPAR-delta in Vascular Pathophysiology.Effect of ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in human lung cancer cell linesShear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells.Regulation of Cell Proliferation and Differentiation by PPARbeta/delta.Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer.Evodiamine inhibits PDGF‑BB‑induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress.PPARs as therapeutic targets in cardiovascular disease.Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.An integrated approach for the mechanisms responsible for atherosclerotic plaque regressionSuppression of PPARβ, and DHA treatment, inhibit NaV1.5 and NHE-1 pro-invasive activities.The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells.Telmisartan modulates mitochondrial function in vascular smooth muscle cells.A selective peroxisome proliferator-activated receptor-β/δ agonist attenuates neointimal hyperplasia after wire-mediated arterial injury.The PPARδ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARδ.
P2860
Q24642728-5918CC1C-2EEC-436E-9D86-FDBB6287967CQ28280615-60B0B1B7-F106-488E-B5B1-9234738E7BA1Q34538852-396946C0-FBDE-452C-80D5-71C6B236E6FAQ34620720-BAD57FF0-5ADD-405F-AE7D-6B7B1285C7C7Q34673917-9F2B8D9F-0E6A-4AAA-8779-026493D913EBQ35548912-83A0F2EB-74D0-4D17-B53E-9616373E0397Q35636191-C2189C2B-E342-4226-B718-FD6C24E6576EQ35795489-38F9A15F-E0BE-40C8-9FDD-7C6936128D61Q35956552-C310B3FC-67E3-48B8-8D35-1392E76691A1Q36287741-A7B1226C-6379-490B-BD4C-1826FFA5ED48Q36857534-E15F3037-F62C-48C6-BC0E-AD9FF3AA15E0Q37037802-E92C7528-4AD1-418A-BDA9-BCFEFC5B713EQ37121931-4D9F2CC3-95ED-4B63-BA1E-09C172D7C329Q37170052-FCF86EC9-6C06-4342-AE1D-A6AE2EA8B87AQ37278862-AB554DB4-BAAE-455D-B809-680BDAD6ACF2Q37388607-70C2E1DC-4866-4C99-AC8D-4B1F934ACD25Q37403477-BFDF10A6-9AFD-43FD-8B42-CCB338CA51ABQ37790384-99A28E5A-99EB-49CB-B4CD-DF455184E3F8Q38128537-B63D79C4-3FE8-45C3-8E5E-07E2F75EF384Q38963714-DD924B3C-0F4E-4C34-8A4E-453A91074A06Q38975907-D51854DC-B0FC-4A8A-B209-CAF2A4901991Q39185669-BF7D0E68-7FB1-4BF1-AE71-6388AEEB6459Q40630791-7B3F96FE-A842-4D18-9E13-6683382CAFB3Q46089688-A82AA63D-8D3B-4FE6-96A2-6E3E23DF6A1FQ47858945-E6FFC7DC-C43D-4802-A63F-E54056378D1EQ53193081-2356417E-54E1-4B9B-B21A-0B75A57C8E87
P2860
PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle
description
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im Februar 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2009/02/01)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/02/01)
@nl
наукова стаття, опублікована в лютому 2009
@uk
مقالة علمية (نشرت في فبراير 2009)
@ar
name
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@ast
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@en
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@nl
type
label
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@ast
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@en
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@nl
prefLabel
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@ast
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@en
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@nl
P2093
P3181
P1433
P1476
PPAR delta agonist L-165041 in ...... n via inhibition of cell cycle
@en
P2093
Hye-Eun Choi
Hyoung-Hee Lee
Hyun-Joung Lim
Hyun-Young Park
Jin-Hee Park
Kuy-Sook Lee
Kyung-Sook Chung
Seahyoung Lee
P304
P3181
P356
10.1016/J.ATHEROSCLEROSIS.2008.05.023
P577
2009-02-01T00:00:00Z